Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) - Research analysts at Cantor Fitzgerald issued their FY2026 EPS estimates for shares of Vertex Pharmaceuticals in a report released on Monday, June 9th. Cantor Fitzgerald analyst C. Gould expects that the pharmaceutical company will post earnings per share of $18.36 for the year. Cantor Fitzgerald currently has a "Overweight" rating and a $535.00 price target on the stock. The consensus estimate for Vertex Pharmaceuticals' current full-year earnings is $15.63 per share.
A number of other equities research analysts also recently issued reports on VRTX. Morgan Stanley lifted their price target on shares of Vertex Pharmaceuticals from $462.00 to $464.00 and gave the company an "equal weight" rating in a research report on Tuesday, May 6th. Royal Bank of Canada upped their price target on shares of Vertex Pharmaceuticals from $420.00 to $423.00 and gave the stock a "sector perform" rating in a research report on Tuesday, May 6th. Wolfe Research cut Vertex Pharmaceuticals from an "outperform" rating to a "peer perform" rating in a research note on Wednesday, May 7th. The Goldman Sachs Group restated a "buy" rating on shares of Vertex Pharmaceuticals in a research report on Tuesday, May 6th. Finally, Scotiabank lowered their target price on Vertex Pharmaceuticals from $450.00 to $442.00 and set a "sector perform" rating on the stock in a research report on Tuesday, May 6th. Fourteen research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $515.04.
View Our Latest Report on VRTX
Vertex Pharmaceuticals Stock Performance
Shares of VRTX stock traded up $7.62 during mid-day trading on Wednesday, hitting $460.06. The stock had a trading volume of 1,074,482 shares, compared to its average volume of 1,416,995. The company's 50-day simple moving average is $462.88 and its 200-day simple moving average is $460.24. Vertex Pharmaceuticals has a fifty-two week low of $377.85 and a fifty-two week high of $519.88. The firm has a market cap of $118.14 billion, a PE ratio of -209.12, a PEG ratio of 2.11 and a beta of 0.41. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.69 and a quick ratio of 2.35.
Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last announced its earnings results on Monday, May 5th. The pharmaceutical company reported $4.06 EPS for the quarter, missing analysts' consensus estimates of $4.29 by ($0.23). The business had revenue of $2.77 billion during the quarter, compared to analysts' expectations of $2.85 billion. Vertex Pharmaceuticals had a negative net margin of 4.86% and a negative return on equity of 2.02%. Vertex Pharmaceuticals's quarterly revenue was up 2.6% on a year-over-year basis. During the same period in the previous year, the company posted $4.76 earnings per share.
Institutional Investors Weigh In On Vertex Pharmaceuticals
A number of large investors have recently bought and sold shares of VRTX. Brighton Jones LLC lifted its position in shares of Vertex Pharmaceuticals by 15.0% during the 4th quarter. Brighton Jones LLC now owns 4,427 shares of the pharmaceutical company's stock worth $1,783,000 after purchasing an additional 579 shares during the last quarter. Golden State Wealth Management LLC acquired a new position in Vertex Pharmaceuticals in the fourth quarter valued at about $37,000. Wingate Wealth Advisors Inc. acquired a new stake in Vertex Pharmaceuticals during the 4th quarter valued at $43,000. Sapient Capital LLC raised its holdings in shares of Vertex Pharmaceuticals by 1.4% in the fourth quarter. Sapient Capital LLC now owns 35,796 shares of the pharmaceutical company's stock valued at $14,415,000 after buying an additional 498 shares during the last quarter. Finally, Summit Trail Advisors LLC grew its stake in shares of Vertex Pharmaceuticals by 35.1% during the fourth quarter. Summit Trail Advisors LLC now owns 4,409 shares of the pharmaceutical company's stock valued at $1,776,000 after purchasing an additional 1,145 shares during the last quarter. 90.96% of the stock is currently owned by institutional investors.
About Vertex Pharmaceuticals
(
Get Free Report)
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.
Featured Articles
Before you consider Vertex Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vertex Pharmaceuticals wasn't on the list.
While Vertex Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
